{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:52:07Z","timestamp":1791561127080,"version":"4.3.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":182,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RF1-NS112153"],"award-info":[{"award-number":["RF1-NS112153"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-NS89757"],"award-info":[{"award-number":["R01-NS89757"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["NeuroImage: Clinical"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.nicl.2026.104031","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:34:25Z","timestamp":1783035265000},"page":"104031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Predicting pattern and spread of brain atrophy and tau deposition in progressive supranuclear palsy"],"prefix":"10.1016","volume":"51","author":[{"given":"Alma","family":"Ghirelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farwa","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehkyoung C.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.G.","family":"Stierwalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Machulda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Agosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis W.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val J.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Josephs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Whitwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nicl.2026.104031_bb0005","series-title":"Progressive supranuclear palsy","author":"Agarwal","year":"2024"},{"key":"10.1016\/j.nicl.2026.104031_bb0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00259-022-05952-0","article-title":"Interplay of tau and functional network connectivity in progressive supranuclear palsy: a [(18)F]PI-2620 PET\/MRI study","volume":"50","author":"Aghakhanyan","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.nicl.2026.104031_bb0015","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/jnnp-2017-317443","article-title":"Tracking brain damage in progressive supranuclear palsy: a longitudinal MRI study","volume":"89","author":"Agosta","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.nicl.2026.104031_bb0020","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/brain\/awm301","article-title":"Clinical and neuropathologic features of progressive supranuclear palsy with severe pallido-nigro-luysial degeneration and axonal dystrophy","volume":"131","author":"Ahmed","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.nicl.2026.104031_bb0025","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00415-018-8815-x","article-title":"[(18)F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation","volume":"265","author":"Ali","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.nicl.2026.104031_bb0030","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/mds.27619","article-title":"Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy","volume":"34","author":"Ali","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nicl.2026.104031_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2025.107939","article-title":"Tau positron emission tomography in the Parkinson and Richardson subtypes of progressive supranuclear palsy","volume":"137","author":"Alster","year":"2025","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.nicl.2026.104031_bb0040","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1044\/2020_AJSLP-20-00126","article-title":"Motor speech disorders and communication limitations in progressive supranuclear palsy","volume":"30","author":"Clark","year":"2021","journal-title":"Am. J. Speech Lang. Pathol."},{"key":"10.1016\/j.nicl.2026.104031_bb0045","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","article-title":"Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial","volume":"27","author":"Dam","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.nicl.2026.104031_bb0050","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jnen\/61.11.935","article-title":"Office of Rare Diseases neuropathologic criteria for corticobasal degeneration","volume":"61","author":"Dickson","year":"2002","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nicl.2026.104031_bb0055","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s12031-011-9589-0","article-title":"Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau)","volume":"45","author":"Dickson","year":"2011","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.nicl.2026.104031_bb0060","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1212\/WNL.0000000000003305","article-title":"Progression of brain atrophy in PSP and CBS over 6 months and 1 year","volume":"87","author":"Dutt","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nicl.2026.104031_bb0065","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/ana.25893","article-title":"Sensitivity-specificity of tau and amyloid \u03b2 positron emission tomography in frontotemporal lobar degeneration","volume":"88","author":"Ghirelli","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nicl.2026.104031_bb0070","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/jnnp-2016-314956","article-title":"Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis","volume":"88","author":"Glasmacher","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.nicl.2026.104031_bb0075","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/mds.28901","article-title":"Brainstem biomarkers of clinical variant and pathology in progressive supranuclear palsy","volume":"37","author":"Grijalva","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nicl.2026.104031_bb0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.parkreldis.2021.01.015","article-title":"Association of PSP phenotypes with survival: a brain-bank study","volume":"84","author":"Guasp","year":"2021","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.nicl.2026.104031_bb0085","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1212\/WNL.44.11.2015","article-title":"Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy)","volume":"44","author":"Hauw","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.nicl.2026.104031_bb0090","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nicl.2026.104031_bb0095","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/mds.26973","article-title":"Longitudinal magnetic resonance imaging in progressive supranuclear palsy: a new combined score for clinical trials","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nicl.2026.104031_bb0100","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S1474-4422(20)30489-0","article-title":"Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial","volume":"20","author":"H\u00f6glinger","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nicl.2026.104031_bb0105","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.28822","article-title":"Autopsy validation of progressive supranuclear palsy-predominant speech\/language disorder criteria","volume":"37","author":"Hokelekli","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nicl.2026.104031_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104835","article-title":"Uncovering distinct progression patterns of tau deposition in progressive supranuclear palsy using [(18)F]Florzolotau PET imaging and subtype\/stage inference algorithm","volume":"97","author":"Hong","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.nicl.2026.104031_bb0115","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/brain\/awv338","article-title":"Cascading network failure across the Alzheimer's disease spectrum","volume":"139","author":"Jones","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.nicl.2026.104031_bb0120","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/01.jnen.0000218446.38158.61","article-title":"Atypical progressive supranuclear palsy with corticospinal tract degeneration","volume":"65","author":"Josephs","year":"2006","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nicl.2026.104031_bb0125","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.parkreldis.2005.08.007","article-title":"The relationship between histopathological features of progressive supranuclear palsy and disease duration","volume":"12","author":"Josephs","year":"2006","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.nicl.2026.104031_bb0130","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/mds.25437","article-title":"Modeling trajectories of regional volume loss in progressive supranuclear palsy","volume":"28","author":"Josephs","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nicl.2026.104031_bb0135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","article-title":"Distribution patterns of tau pathology in progressive supranuclear palsy","volume":"140","author":"Kovacs","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nicl.2026.104031_bb0140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neulet.2003.09.075","article-title":"Alpha-synuclein immunoreactivity in neuronal nuclear inclusions and neurites in multiple system atrophy","volume":"354","author":"Lin","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nicl.2026.104031_bb0145","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/nan.12037","article-title":"Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant","volume":"40","author":"Ling","year":"2014","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.nicl.2026.104031_bb0150","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","article-title":"An autoradiographic evaluation of AV-1451 tau PET in dementia","volume":"4","author":"Lowe","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.nicl.2026.104031_bb0155","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40478-017-0482-0","article-title":"Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case","volume":"5","author":"Marqui\u00e9","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.nicl.2026.104031_bb0160","doi-asserted-by":"crossref","first-page":"fcae113","DOI":"10.1093\/braincomms\/fcae113","article-title":"Histologic tau lesions and magnetic resonance imaging biomarkers differ across two progressive supranuclear palsy variants","volume":"6","author":"Orlandi","year":"2024","journal-title":"Brain Commun"},{"key":"10.1016\/j.nicl.2026.104031_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105290","article-title":"Longitudinal clinical decline and baseline predictors in progressive supranuclear palsy","volume":"107","author":"Pavone","year":"2023","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.nicl.2026.104031_bb0170","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/mds.26054","article-title":"The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases","volume":"29","author":"Respondek","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nicl.2026.104031_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.814768","article-title":"Temporal progression patterns of brain atrophy in Corticobasal syndrome and progressive supranuclear palsy revealed by subtype and stage inference (SuStaIn)","volume":"13","author":"Saito","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.nicl.2026.104031_bb0180","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/mds.27816","article-title":"Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy","volume":"34","author":"Sakae","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nicl.2026.104031_bb0185","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jalz.2016.01.003","article-title":"Characterization of tau positron emission tomography tracer [(18)F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias","volume":"12","author":"Sander","year":"2016","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nicl.2026.104031_bb0190","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","article-title":"Tau kinetics in neurons and the human central nervous system","volume":"97","author":"Sato","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.nicl.2026.104031_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2024.120509","article-title":"Direct comparison between (18)F-Flortaucipir tau PET and quantitative susceptibility mapping in progressive supranuclear palsy","volume":"286","author":"Satoh","year":"2024","journal-title":"Neuroimage"},{"key":"10.1016\/j.nicl.2026.104031_bb0200","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ana.27286","article-title":"Uncovering image-driven subtypes with distinct pathology and clinical course in autopsy-confirmed four repeat tauopathies","volume":"98","author":"Satoh","year":"2025","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nicl.2026.104031_bb0205","doi-asserted-by":"crossref","first-page":"fcad048","DOI":"10.1093\/braincomms\/fcad048","article-title":"Uncovering spatiotemporal patterns of atrophy in progressive supranuclear palsy using unsupervised machine learning","volume":"5","author":"Scotton","year":"2023","journal-title":"Brain Commun"},{"key":"10.1016\/j.nicl.2026.104031_bb0210","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.parkreldis.2019.07.001","article-title":"Multimodal neuroimaging relationships in progressive supranuclear palsy","volume":"66","author":"Sintini","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.nicl.2026.104031_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005072-199301000-00001","article-title":"Neuropathology of mitochondrial encephalomyopathies due to mitochondrial DNA defects","volume":"52","author":"Sparaco","year":"1993","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nicl.2026.104031_bb0220","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/mds.20478","article-title":"Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome","volume":"20","author":"Tsuboi","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nicl.2026.104031_bb0225","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1212\/WNL.0b013e3181feb2e8","article-title":"Imaging correlates of pathology in corticobasal syndrome","volume":"75","author":"Whitwell","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.nicl.2026.104031_bb0230","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/mds.26834","article-title":"[(18) F]AV-1451 tau positron emission tomography in progressive supranuclear palsy","volume":"32","author":"Whitwell","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nicl.2026.104031_bb0235","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/mds.27546","article-title":"MRI outperforms [18F]AV-1451 PET as a longitudinal biomarker in progressive supranuclear palsy","volume":"34","author":"Whitwell","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nicl.2026.104031_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2019.102152","article-title":"Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants","volume":"25","author":"Whitwell","year":"2020","journal-title":"Neuroimage Clin"},{"key":"10.1016\/j.nicl.2026.104031_bb0245","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1038\/s41467-018-05892-0","article-title":"Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with subtype and stage inference","volume":"9","author":"Young","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.nicl.2026.104031_bb0250","doi-asserted-by":"crossref","first-page":"e941","DOI":"10.1212\/WNL.0000000000012410","article-title":"Characterizing the clinical features and atrophy patterns of MAPT-related frontotemporal dementia with disease progression Modeling","volume":"97","author":"Young","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.nicl.2026.104031_bb0255","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41531-023-00556-3","article-title":"Two distinct trajectories of clinical and neurodegeneration events in Parkinson's disease","volume":"9","author":"Zhou","year":"2023","journal-title":"NPJ Parkinsons Dis"}],"container-title":["NeuroImage: Clinical"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213158226000902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213158226000902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:12:30Z","timestamp":1791558750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213158226000902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":51,"alternative-id":["S2213158226000902"],"URL":"https:\/\/doi.org\/10.1016\/j.nicl.2026.104031","relation":{},"ISSN":["2213-1582"],"issn-type":[{"value":"2213-1582","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting pattern and spread of brain atrophy and tau deposition in progressive supranuclear palsy","name":"articletitle","label":"Article Title"},{"value":"NeuroImage: Clinical","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nicl.2026.104031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104031"}}